Publication, Part of Medicines and Pregnancy Registry
[MI] Medicines and Pregnancy Registry - Antiepileptic use in females aged 0 to 54 in England: April 2018 to September 2023
Summary
NHS England is working in partnership with the Medicines and Healthcare products Regulatory Agency (MHRA) to develop comprehensive national Medicines and Pregnancy Registries which can give a better understanding of the use, benefits, and risks of medicines taken in pregnancy.
The objectives are to:
• use data to generate evidence on the use, benefits, and risks of medicines prescribed during pregnancy
• enable the health and care system including medicines regulators to make informed decisions to ensure the safe prescribing of medicines in pregnancy
• support continued follow up of women prescribed medicines in pregnancy and their children
• minimise the burden imposed on health and care providers and their commissioners by a registry whilst maximising coverage through central data linkage and analysis
This report is an analysis of linking existing administrative patient data using Prescribing data, Maternity Services Dataset and Hospital Episodes Statistics (see Data Sources page for further information). This has been developed as a proof of concept, to establish the use and value of these data sets in supporting robust and sustainable medicine registries. The data produced are designed to support the MHRA in monitoring the level of success of the valproate pregnancy prevention plan (PPP) and to enable the wider health and care system to further understand outcomes for women prescribed valproate during pregnancy and their children and consequently to improve patient care.
To monitor the implementation of and adherence to the valproate PPP, understand changes in the use of antiepileptics and the impact of these changes on women and their children, and to facilitate further research into outcomes following the use of antiepileptics in pregnancy, MHRA and NHS England are developing an antiepileptics registry.
This is the seventh release in the series and users are advised to always use the latest publication for the most up-to-date figures.
Further work to validate pregnancies from the Maternity Services Dataset (MSDS) has been undertaken in the latest publication. The report now utilises recorded date of birth (where this information is available) above previous use of estimated delivery date. In addition, any overlapping pregnancies attributed to the same female (owing to conflicting source data) are now subject to additional validation procedures to deduplicate wherever possible. This is the first publication to be affected by the above changes and will include revisions to all previously published data. Users are advised to always use the latest publication for the correct figures. Results from this publication should not be directly compared to previous releases.
Further updated reports, as the registry develops, will be available on a regular basis subject to ongoing discussions and appropriate arrangements being in place.
Highlights
Warning
It is important women do not stop taking their antiepileptic medicine without first discussing it with their doctor. Women receiving treatment who anticipate they may become pregnant at any point in the future are advised to discuss their treatment with a healthcare professional.
Feedback
We welcome any user feedback about this publication, you can provide this by email to [email protected]
Key Facts
53,395 females (aged 0 - 54) were prescribed valproate on one or more occasion between April 2018 and September 2023
Of which, 16,918 females were prescribed valproate in September 2023. A reduction of 10,523 from 27,441 in April 2018 to 16,918 in September 2023
Valproate prescribing and pregnancy
for conceptions identified since April 2018
Resources
Last edited: 22 March 2024 2:34 pm